Savara Inc.
http://www.savarapharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Savara Inc.
Finance Watch: Alumis Launches IPO In Market Less Receptive Than Expected
Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.
Savara’s Persistence May Pay Off In Rare Lung Disease
Five years after a Phase III failure, Savara reports pivotal data supporting approval of molgramostim as the first drug for autoimmune pulmonary alveolar proteinosis.
Finance Watch: Apogee, Sagimet Launch First Big US IPOs Of The Summer
Public Company Edition: Apogee grossed $300m and Sagimet raised $85m in the biggest initial public offerings in the US since Acelyrin’s $540m IPO in May. Also, Bausch entered into a $600m funding facility with KKR, Bicycle raised $200m in a FOPO and Caribou garnered $150m from an offering and Pfizer.
Potential Milestone Year Ahead For Korean NASH Contenders
Scrip takes a look at key recent drug development activities in the NASH area by Korean firms, which are now pursuing the global development of their candidates as they look to leverage innovation to expand internationally.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
-
Biotechnology
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
-
- Serendex ApS, Mast Therapeutics, Inc.
- SD Pharmaceuticals Inc
- Savara ApS
- Synthrx, Inc.
- Aires Pharmaceuticals, Inc.
- Savara Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice